Pharma BD Deal Intelligence
Value destroyed: $20M all-stock deal ended with the entire combined R&D portfolio sold for $4M cash three years later, followed by company wind-down
Full analysis, sources & comparables →Inflazyme exchanged 12,684,055 common shares for AdProTech, valued at ~C$20M, gaining a complement-inhibition platform, a Phase IIa rheumatoid arthritis asset,…
Inflazyme cuts jobs after drug trial failure — within ~18 months of the AdProTech acquisition, the combined entity faced clinical setbacks that triggered…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
April 2004; 12.7M Inflazyme shares; UK biotech; complement system inhibitors; ex-GSK spinout
Value destroyed: $20M all-stock deal ended with the entire combined R&D portfolio sold for $4M cash three years later, followed by company wind-down
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Inflazyme Pharmaceuticals Ltd. / AdProTech Limited (this deal) | 2004 | $20M | 8 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2004 | $7.6B | 84 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Sanofi-Synthelabo SA / Aventis SA | 2004 | $65.0B | 80 |
| Genzyme Corporation / ILEX Oncology Inc. | 2004 | $1.0B | 66 |
| Hospira Inc. / Abbott Hospital Products Division | 2004 | — | 54 |
← Browse all deals · How we score deals
More: 2004 deals